Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Rakel Brendsdal Forthun"'
Autor:
Kjersti Tjensvoll, Morten Lapin, Bjørnar Gilje, Herish Garresori, Satu Oltedal, Rakel Brendsdal Forthun, Anders Molven, Yves Rozenholc, Oddmund Nordgård
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Circulating tumor DNA (ctDNA) analysis has emerged as a clinically useful tool for cancer diagnostics and treatment monitoring. However, ctDNA detection is complicated by low DNA concentrations and technical challenges. Here we describe our
Externí odkaz:
https://doaj.org/article/da1fe73c4390450aaa2f5f40ab495524
Autor:
Håkon Reikvam, Randi Hovland, Rakel Brendsdal Forthun, Sigrid Erdal, Bjørn Tore Gjertsen, Hanne Fredly, Øystein Bruserud
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-13 (2017)
Abstract Background Acute myeloid leukemia (AML) is an aggressive malignancy only cured by intensive therapy. However, many elderly and unfit patients cannot receive such treatment due to an unacceptable risk of treatment-related morbidity and mortal
Externí odkaz:
https://doaj.org/article/30365bf5c7b446b8a88ae69413f64ea9
Autor:
Rakel Brendsdal Forthun, Tanima Sengupta, Hanne Kim Skjeldam, Jessica Margareta Lindvall, Emmet McCormack, Bjørn Tore Gjertsen, Hilde Nilsen
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e48992 (2012)
The mechanisms of successful epigenetic reprogramming in cancer are not well characterized as they involve coordinated removal of repressive marks and deposition of activating marks by a large number of histone and DNA modification enzymes. Here, we
Externí odkaz:
https://doaj.org/article/fb43e957da464fc89c2e8ec223afbe47
Autor:
Bjarte Skoe Erikstein, Aymen Bushra Ahmed, Rakel Brendsdal Forthun, Friedemann Leh, Bjørn Tore Gjertsen, Håkon Reikvam
Publikováno v:
Journal of Hematology. 12:92-99
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e26fcfc714c1ef8515890ff64b6d4fb
https://doi.org/10.14740/jh1107
https://doi.org/10.14740/jh1107
Autor:
Bjørn Tore Gjertsen, Anders Molven, Kaoru Tohyama, Mihaela Popa, Astrid Olsnes Kittang, Monica Hellesøy, Biju Parekkadan, Rakel Brendsdal Forthun, Jungwoo Lee, Sahba Shafiee, Randi Hovland, Pascal Gelebart, Emmet McCormack
Publikováno v:
Br J Haematol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f33ebf6b01b15d8268fae445f102f9f
https://doi.org/10.1111/bjh.17372
https://doi.org/10.1111/bjh.17372
Autor:
Hans Petter Brodal, Hanne E. Puntervoll, Leonardo A. Meza-Zepeda, Lars Birger Aasheim, Bjørn Tore Gjertsen, Rakel Brendsdal Forthun, Randi Hovland, Stian Knappskog, Oddbjørn Straume, Cornelia Schuster, Heidi M. Namløs
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-15 (2019)
Scientific Reports
Scientific Reports
Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to predict and monitor treatment response, cancer and angiogenesis relevant mutations in tumour and circulating tumour DNA (ctDNA) were investigated in 26 metastat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a2ad5cdb7deceeb726dcdcbca8f1150
http://link.springer.com/article/10.1038/s41598-019-53917-5
http://link.springer.com/article/10.1038/s41598-019-53917-5
Autor:
Man Hung Choi, Erling Tjora, Anders Molven, Rakel Brendsdal Forthun, Helge Ræder, Randi Hovland, Trond Engjom
Publikováno v:
Pancreatology
Background Maturity-onset diabetes of the young type 8 (MODY8 or CEL-MODY) is an inherited pancreatic disease characterized by chronic inflammation of the pancreas and diabetes. It is not known whether MODY8 patients have increased risk for developin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8b0a6735158a06863616dfc96516c36
https://hdl.handle.net/11250/2800308
https://hdl.handle.net/11250/2800308
Autor:
Liv T. N. Osnes, Trude Høysæter, Signe Spetalen, Trine Prescott, Atle Brendehaug, Anette K Eek, Rakel Brendsdal Forthun, Randi Hovland, Monica Cheng Munthe-Kaas
Publikováno v:
Journal of pediatric hematology/oncology. 43(4)
Dysregulated tyrosine kinases in myeloid/lymphoid neoplasms with eosinophilia are rare, but do occur in children. To increase awareness of this diagnosis, we present a child who was diagnosed after a 3-year disease history. The patient was initially
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfb5c604d606ecd3302bc792f616e527
https://pubmed.ncbi.nlm.nih.gov/32852395
https://pubmed.ncbi.nlm.nih.gov/32852395
Autor:
Frode S. Berven, Øystein Bruserud, Elise Aasebø, Rakel Brendsdal Forthun, Bjørn Tore Gjertsen, Siv Lise Bedringaas, J.D. Rasinger, Frode Selheim
Publikováno v:
Journal of Proteomics. 173:32-41
Acute myeloid leukaemia (AML) is an aggressive blood cancer characterized by a distinct block in differentiation of myeloid progenitors, recurrent chromosomal translocations and gene mutations of which > 50% involve signal transduction through dysreg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b53467fe5ca86d5d1281dfb1ae7d3bdf
https://doi.org/10.1016/j.jprot.2017.11.014
https://doi.org/10.1016/j.jprot.2017.11.014
Autor:
Randi Hovland, Annette K. Brenner, Håkon Reikvam, Sushma Bartaula-Brevik, Rakel Brendsdal Forthun, Ida Sofie Grønningsæter, Øystein Bruserud, Elise Aasebø
Publikováno v:
Journal of Clinical Medicine
Volume 8
Issue 7
Journal of Clinical Medicine, Vol 8, Iss 7, p 970 (2019)
Journal of clinical medicine
Volume 8
Issue 7
Journal of Clinical Medicine, Vol 8, Iss 7, p 970 (2019)
Journal of clinical medicine
Acute myeloid leukemia (AML) is a heterogeneous disease, and this heterogeneity includes the capacity of constitutive release of extracellular soluble mediators by AML cells. We investigated whether this capacity is associated with molecular genetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c097a63d711f35e31cc9a3f27b747bbd